InkVivo

Swiss biotech spin-off from ETH Zurich, addresses a critical challenge in drug development: improving how medicines are formulated and delivered to enhance efficacy and patient outcomes. Its proprietary polymer platform enables faster formulation optimization and more precise delivery of oral and long-acting injectable drugs.